Targeting a key protein complex to develop new treatments for Human African Trypanosomiasis
The catalytic core of the proteasome as a drug target to treat Human African Trypanosomiasis
This study is looking for new and safer treatments for Human African Trypanosomiasis (HAT) by targeting a specific part of the parasite that causes the disease, and it's designed to help people who are affected by this illness.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Diego NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project ID | NIH-10677879 on NIH RePORTER |
What this research studies
This research focuses on Human African Trypanosomiasis (HAT), a disease caused by the Trypanosoma brucei parasite, which is transmitted through tse-tse fly bites. The project aims to identify and develop new drug therapies by targeting the proteasome, a protein complex that regulates protein degradation in cells. By using advanced techniques like mass spectrometry, the researchers will analyze how this proteasome can be inhibited to effectively kill the parasite. The goal is to create more effective and less toxic treatments for patients suffering from HAT.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Human African Trypanosomiasis, particularly those in the early stages of the disease.
Not a fit: Patients with advanced stages of HAT or those who have not been diagnosed with the disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of safer and more effective treatments for Human African Trypanosomiasis.
How similar studies have performed: Previous research has shown promise in targeting proteasomes for drug development, indicating potential success for this novel approach.
Where this research is happening
La Jolla, United States
- University of California, San Diego — La Jolla, United States (Active)
Researchers
- Principal investigator: Caffrey, Conor — University of California, San Diego
- Study coordinator: Caffrey, Conor
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.